S. Antonia

Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma

Matthew B. Schabath, E A Welsh, William J. Fulp et al. · Oncogene · 2015 · 445 citations

Medicine, Genetics, Oncology +15

Clinical activity, safety and predictive biomarkers results from a phase Ia atezolizumab (atezo) trial in extensive-stage small cell lung cancer (ES-SCLC)

Lecia V. Sequist, AK Chiang, Jennifer L. Gilbert et al. · Annals of Oncology · 2016 · 42 citations · Full text

Medicine, Oncology, Pharmacology +14

Overcoming tumor antigen anergy in human malignancies using the novel indeolamine 2,3-dioxygenase (IDO) enzyme inhibitor, 1-methyl-D-tryptophan (1MT)

Hatem Soliman, S. Antonia, Delaney E. Sullivan et al. · Journal of Clinical Oncology · 2009 · 41 citations

Medicine, Oncology, Pharmacology +14

Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial

Suresh Senan, Mustafa Özgüroğlu, Davey B. Daniel et al. · ESMO Open · 2022 · 25 citations · Full text

Medicine, Oncology, Radiation Oncology +16

A phase I study of YM155, a novel survivin suppressant, administered by 168 hour continuous infusion to patients with advanced solid tumors

A. W. Tolcher, S. Antonia, Lionel D. Lewis et al. · Journal of Clinical Oncology · 2006 · 21 citations

Medicine, Oncology, Pharmacology +17